Literature DB >> 10587796

High-resolution computed tomography in the evaluation of fibrosing alveolitis.

D M Hansell1.   

Abstract

High-resolution computed tomography (HRCT) is now widely used in the investigation of patients with suspected or known diffuse lung disease. This article reviews some of the technical aspects of HRCT and the pathologic considerations that should be appreciated in the context of diagnosing fibrosing alveolitis. The precise quantitation of disease extent and characterization of disease pattern on HRCT has been used to provide new insights about the prognosis and pathophysiology of fibrosing lung disease.

Entities:  

Mesh:

Year:  1999        PMID: 10587796     DOI: 10.1016/s0272-5231(05)70253-7

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN: 0272-5231            Impact factor:   2.878


  4 in total

Review 1.  Assessment of pulmonary hypertension by CT and MR imaging.

Authors:  Sebastian Ley; Karl-Friedrich Kreitner; Christian Fink; Claus P Heussel; Mathias M Borst; Hans-Ulrich Kauczor
Journal:  Eur Radiol       Date:  2004-01-23       Impact factor: 5.315

2.  Ultra-short echo time (UTE) MR imaging of the lung: comparison between normal and emphysematous lungs in mutant mice.

Authors:  Masaya Takahashi; Osamu Togao; Makoto Obara; Marc van Cauteren; Yoshiharu Ohno; Shigehiro Doi; Makoto Kuro-o; Craig Malloy; Connie C Hsia; Ivan Dimitrov
Journal:  J Magn Reson Imaging       Date:  2010-08       Impact factor: 4.813

3.  pDCs in lung and skin fibrosis in a bleomycin-induced model and patients with systemic sclerosis.

Authors:  Suzanne Kafaja; Isela Valera; Anagha A Divekar; Rajan Saggar; Fereidoun Abtin; Daniel E Furst; Dinesh Khanna; Ram Raj Singh
Journal:  JCI Insight       Date:  2018-05-03

4.  Characterization of lung cancer by amide proton transfer (APT) imaging: an in-vivo study in an orthotopic mouse model.

Authors:  Osamu Togao; Chase W Kessinger; Gang Huang; Todd C Soesbe; Koji Sagiyama; Ivan Dimitrov; A Dean Sherry; Jinming Gao; Masaya Takahashi
Journal:  PLoS One       Date:  2013-10-15       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.